Pharmaceutical

MC-232 by MC2 Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval

MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa.

Oct 3, 2023 - 20:00
MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa.
Read the original article

Tags:

Previous Article

Super DC Vaccine by Shanghai Cell Therapy Group for Solid Tumor: Likelihood of A...

Next Article

CD123-targeted CAR-NK by Chongqing Precision Biotech for Natural Killer Cell Lym...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Travere kidney drug narrowly fails confirmatory trial following FDA approval

STAT+: Travere kidney drug narrowly fails confirmatory ...

Sep 22, 2023

Cidara to continue its CD388 influenza programme despite Janssen’s contrary decision

Cidara to continue its CD388 influenza programme despit...

Jul 21, 2023

STAT+: Truvian presents data for its desktop blood-testing device in a field still in Theranos’s shadow

STAT+: Truvian presents data for its desktop blood-test...

Jul 26, 2023